Resumen

MONTIEL-JAROLIN, Dora et al. Report of a case of thrombocytopenia and thrombosis secondary to the vaccine chAdOx1 nCov-19. Rev. cient. cienc. salud [online]. 2021, vol.3, n.2, pp.120-125. ISSN 2664-2891.  https://doi.org/10.53732/rccsalud/03.02.2021.120.

Introduction. The COVID-19 vaccine, AstraZeneca, may lead to the development of antibodies against platelet factor 4, and trigger manifestations of thrombocytopenia associated with thrombotic events of unusual location. A case of a patient with thrombosis associated with the Astrazeneka vaccine and admitted to the National Hospital in August 2021 is presented. Clinical case: A 54-year-old woman from Yaguaron, received the Astrazeneca vaccine on June 19th, 2021, 26 days later she presented multiple ecchymotic lesions in lower limbs with no history of trauma, gingivorrhagia, epistaxis in moderate quantity. Due to a platelet count lower than 10,000/ mm3, she was admitted to the Hospital. She did not receive heparin. Vital signs were normal, BMI 25, platelet count <10,000 per mm3, prothrombin time 89%, activated partial thromboplastin time 28 seconds, other hematological parameters normal. Antinuclear antibody (ANA), anti DNA, antiproteinase 3, anti myeloperoxidase: negative, c3 and c4 normal. Negative IgM serology for toxoplasmosis, cytomegalovirus, herpes, rubella, Chagas, HIV, hepatitis B, C. Lower limb venous echodpler shows bilateral parva saphenous vein thrombosis. The patient is treated with pulses of methylprednisolone 1g / 3 days, followed by oral prednisone 1mg kg / p / day, with recovery of platelets. An anti-platelet factor 4 antibody test was not performed. Conclusion: due to the temporal relationship between the administration of the vaccine and the appearance of thrombocytopenia and thrombosis, this case may be considered as an adverse effect of the Astrazeneka vaccine.

Palabras clave : thrombocytopenia; thrombosis; vaccine; secondary effect.

        · resumen en Español     · texto en Español     · Español ( pdf )